trending Market Intelligence /marketintelligence/en/news-insights/trending/RjXHwodXRKoi_lkp2cv7Mg2 content esgSubNav
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

Sundrug fiscal Q4 profit falls YOY

Blog

Message in a (Word)Cloud

Six trends shaping the industries and sectors we cover in 2021

Six trends shaping the industries and sectors we cover in 2021

Blog

CUSIP Request Volume Surges in December, Pushing Full-Year 2020 Volumes Past 2019 Totals


Sundrug fiscal Q4 profit falls YOY

Sundrug Co. Ltd. said its normalized net income for the fiscal fourth quarter ended March 31 amounted to ¥36.85 per share, a decrease from ¥37.72 per share in the year-earlier period.

Normalized net income, which excludes unusual gains or losses on a pre- and after-tax basis, was ¥4.46 billion, a decrease of 6.3% from ¥4.75 billion in the prior-year period.

The normalized profit margin dropped to 3.9% from 4.1% in the year-earlier period.

Total revenue declined on an annual basis to ¥113.04 billion from ¥116.77 billion, and total operating expenses fell year over year to ¥106.08 billion from ¥109.42 billion.

Reported net income increased 39.6% year over year to ¥4.37 billion, or ¥36.14 per share, from ¥3.13 billion, or ¥24.83 per share.

For the year, the company's normalized net income totaled ¥135.14 per share, a decrease of 5.3% from ¥142.70 per share in the prior year.

Normalized net income was ¥16.57 billion, a decline of 7.9% from ¥17.99 billion in the prior year.

Full-year total revenue totaled ¥445.82 billion, compared with ¥447.82 billion in the prior year, and total operating expenses totaled ¥419.89 billion, compared with ¥419.76 billion in the year-earlier period.

The company said reported net income increased on an annual basis to ¥16.36 billion, or ¥133.48 per share, in the full year, from ¥15.75 billion, or ¥124.98 per share.

As of June 22, US$1 was equivalent to ¥123.23.